Clinical trials: Sunitinib
Cancer
To Assess the Interaction Between Sunitinib and Ketoconazole to Reduce the Dose and Cost of Sunitinib
Sunitinib is an ATP competitive tyrosine kinase inhibitor of several membrane receptors including VEGFR-1, -2, and -3, PDGFR-α and -β, c-KIT, CSF-1R, FLT-3, and RET.
- Trial name
- NCT01548170
- Testing
- Sunitinib, Sunitinib and Ketoconazol, Sunitiinb and Ketoconazol
- Where
- Spain
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
Renal Cell Cancer Metastatic, Hypertension
Sunitinib Treatment on Tissue Sodium Accumulation (TSS2)
Here, it is investigated how sunitinib, a tyrosine kinase-inhibitor targeting vascular endothelial growth factor receptors, might influence sodium homeostasis in the skin and if this is related to a well-described treatment…
- Conditions
- Renal Cell Cancer Metastatic, Hypertension, Sodium Imbalance
- Trial name
- NCT04368546
- Testing
- Sunitinib
- Where
- Germany
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Charite University, Berlin, Germany
Renal Cell Carcinoma, GIST
Study of the Immunoresponse in Patients Treated With a Tyrosine Kinase Inhibitor
In this study the researchers investigate the influence of the tyrosine kinase inhibitors sunitinib and sorafenib, on the normal humoral and cellular immuno response to influenza vaccination in patients with metastases of renal…
- Trial name
- NCT00979381
- Testing
- influenza vaccine
- Where
- Netherlands
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Radboud University Medical Center
Gastrointestinal Stromal Tumors, Renal Cell Carcinoma
A Bioequivalence Study of Sunitinib Malate Capsules.
A randomized, open, two-period, two-sequence crossover trial design used to assess the pharmacokinetics and safety of Sunitinib Malate Capsules in healthy volunteers under fed condition, and compare the bioequivalence of…
- Conditions
- Gastrointestinal Stromal Tumors, Renal Cell Carcinoma, Pancreatic Neuroendocrine Tumor
- Trial name
- NCT05800106
- Testing
- Sunitinib malate capsules generic product, Sunitinib malate capsules reference product
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Blood Pressure
An Explorative Study on the Pharmacokinetics and Pharmacodynamics of Sunitinib in Healthy Volunteers
The study is conducted: to investigate the influence of sunitinib (study drug) on the plasma biomarkers VEGF-A, VEGF-C, soluble VEGFR-2, and soluble VEGFR-3 (vessel endothelial growth factors) and on the blood pressure; to…
- Trial name
- NCT00904657
- Testing
- sunitinib (Sutent)
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- University of Cologne
Urinary Bladder Neoplasms
Activity Study of Sunitinib In Metastatic Pretreated Urothelial Cancer
Gemcitabine and cisplatin represent the standard first-line chemotherapy in metastatic bladder carcinoma. This regimen has replaced in most centers the MVAC combination showing a similar efficacy but less toxicity.
- Trial name
- NCT00818350
- Testing
- SUNITINIB
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Campania Younger Oncologists Association
Bioequivalence
The Bioequivalence Study of Two Sunitinib Products in Capsules 50 mg in Healthy Volunteers Under Fasting Conditions
The study is designed in accordance with the Eurasian Economic Union (EAEU) regulatory guidelines, with the aim of characterizing the bioavailability of two pharmaceutical products of sunitinib in healthy adult volunteers.
- Trial name
- NCT05218616
- Testing
- Aviga, capsules 50 mg / Sutent®, capsules 50 mg, Sutent®, capsules 50 mg / Aviga, capsules 50 mg
- Where
- Belarus
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- JLLC NatiVita
Adenoid Cystic Carcinoma, Salivary Gland Cancer
A Study of Sunitinib in Recurrent and/or Metastatic Adenoid Cystic Carcinoma of the Salivary Glands
This is a phase II study to evaluate the effectiveness of study drug sunitinib malate in patients with recurrent and/or metastatic adenoid cystic carcinomas of the salivary gland.
- Trial name
- NCT00886132
- Testing
- Sunitinib
- Where
- Canada
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- University Health Network, Toronto